全文获取类型
收费全文 | 15281篇 |
免费 | 1431篇 |
国内免费 | 26篇 |
专业分类
耳鼻咽喉 | 218篇 |
儿科学 | 579篇 |
妇产科学 | 405篇 |
基础医学 | 1902篇 |
口腔科学 | 159篇 |
临床医学 | 1663篇 |
内科学 | 2831篇 |
皮肤病学 | 281篇 |
神经病学 | 1623篇 |
特种医学 | 370篇 |
外国民族医学 | 1篇 |
外科学 | 1690篇 |
综合类 | 121篇 |
一般理论 | 21篇 |
预防医学 | 2441篇 |
眼科学 | 367篇 |
药学 | 998篇 |
1篇 | |
中国医学 | 19篇 |
肿瘤学 | 1048篇 |
出版年
2023年 | 292篇 |
2022年 | 230篇 |
2021年 | 864篇 |
2020年 | 558篇 |
2019年 | 827篇 |
2018年 | 877篇 |
2017年 | 596篇 |
2016年 | 616篇 |
2015年 | 603篇 |
2014年 | 762篇 |
2013年 | 925篇 |
2012年 | 1342篇 |
2011年 | 1307篇 |
2010年 | 633篇 |
2009年 | 525篇 |
2008年 | 845篇 |
2007年 | 807篇 |
2006年 | 641篇 |
2005年 | 594篇 |
2004年 | 507篇 |
2003年 | 415篇 |
2002年 | 341篇 |
2001年 | 105篇 |
2000年 | 82篇 |
1999年 | 85篇 |
1998年 | 56篇 |
1997年 | 45篇 |
1996年 | 33篇 |
1995年 | 57篇 |
1994年 | 53篇 |
1993年 | 53篇 |
1992年 | 76篇 |
1991年 | 74篇 |
1990年 | 60篇 |
1989年 | 61篇 |
1988年 | 49篇 |
1987年 | 62篇 |
1986年 | 42篇 |
1985年 | 54篇 |
1984年 | 40篇 |
1983年 | 47篇 |
1982年 | 38篇 |
1981年 | 30篇 |
1980年 | 26篇 |
1979年 | 26篇 |
1978年 | 27篇 |
1977年 | 25篇 |
1976年 | 38篇 |
1973年 | 28篇 |
1971年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
7.
Love Patel Darshan Gandhi Emily Westergard Michael Ornes Matthew Lillyblad Nedaa Skeik 《World journal of radiology》2021,13(3):64-74
As we continue to fight against the current coronavirus disease-2019 (COVID-19) pandemic, healthcare professionals across the globe are trying to answer questions surrounding how to best help patients with the up-to-date available science while awaiting the development of new therapies and mass vaccination. Since early in the pandemic, studies indicated a heightened risk of venous thromboembolism (VTE) in COVID-19 infected patients. There have been differing expert opinions about how to assess pretest probability of VTE in this patient population. This has been partly due to the high prevalence of respiratory failure in this patient population and the use of D-dimer as a prognostic test which is also frequently elevated in patients with COVID-19 in absence of VTE. Some experts have argued for an approach similar to usual care with testing if clinical suspicion is high enough. Some have argued for more routine screening at different points of care. Others have even suggested empiric therapeutic anti-coagulation in moderate to severely ill COVID-19 patients. In the following article, we review and summarize the most current literature in hopes of assisting clinicians in decision making and guidance for when to be concerned for VTE in COVID-19 patients. We also discuss research gaps and share pathways currently being used within our institution. 相似文献
8.
9.
10.
In an article published in this issue of Cancer, D’Arcy et al link the incidence of cancer among recipients of solid organ transplantation (SOT) in the Scientific Registry of Transplant Recipients with data from regional and statewide cancer registries to examine cancer-specific mortality for common malignancies in SOT recipients. This analysis helps to illuminate the role of immune surveillance across a broad range of malignancies and compares the incidence of cancers due to virally mediated oncogenesis (lymphoma, squamous cell carcinoma of the aerodigestive epithelium, and hepatitis-induced liver cancer) with the incidence of other malignancies. The authors’ central finding is that cancer-specific mortality is significantly increased in SOT recipients in comparison with nontransplant recipients for multiple cancers, and the increased cancer incidence is not limited to the effects of viral oncogenesis. The authors document a significant increase in common epithelial malignancies that are currently treated with immune checkpoint antibodies, including melanoma, bladder cancer, colorectal cancer, cancers of the oral cavity/pharynx, kidney cancer, and lung cancer, and this supports the hypothesis that post-SOT immunosuppression affects immune surveillance in these cancers. Provocatively, the authors also document increases in the incidence and mortality of cancers not typically responsive to immune checkpoint therapies, including breast cancer and pancreatic cancer. The findings of D’Arcy et al suggest that immune surveillance controls oncogenesis and tumor progression in a broad range of malignancies and that breast cancer and pancreatic cancer could be sensitive to drugs targeting immune surveillance pathways other than those treated with currently Food and Drug Administration–approved antibodies to CTLA4 and PD-1/PD-L1. 相似文献